drugset / Trial / NCT01548001

Long-term Efficacy of Iguratimod Alone or Iguratimod in Combination With Methotrexate in Patients With Rheumatoid Arthritis

NCT01548001

Phase 4 Unknown 910 enrolled Jiangsu Simcere Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is intended to evaluate the efficacy and safety of Iguratimod alone or Iguratimod in combination with Methotrexate (MTX) versus Methotrexate alone in patients with Rheumatoid Arthritis (RA).

Timeline

Start
2012-05
Primary completion
2016-11
Completion
2017-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Iguratimod Small molecule 25 mg Oral
Subject Methotrexate Small molecule 15 mg Oral

Indications